NCT00163982

Brief Summary

This study is looking at the detection of vasoactive peptides in portal hypertension.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 13, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 14, 2005

Completed
Last Updated

July 26, 2007

Status Verified

September 1, 2005

First QC Date

September 13, 2005

Last Update Submit

July 25, 2007

Conditions

Keywords

HVPG > 12 mmHg

Interventions

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HVPG \>= 12 mmHg

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alfred Hospital

Melbourne, Victoria, 3181, Australia

RECRUITING

MeSH Terms

Conditions

Hypertension, Portal

Interventions

Norfloxacin

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Fluoroquinolones4-QuinolonesQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • William W Kemp, MBBS, FRACP

    The Alfred

    PRINCIPAL INVESTIGATOR

Central Study Contacts

William W Kemp, MBBS, FRACP

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 14, 2005

Last Updated

July 26, 2007

Record last verified: 2005-09

Locations